A large consortium led by the University of Tübingen, the Radboud university medical center Nijmegen and the University of Leicester has acquired a € 15 million grant for the SOLVE-RD research program. The consortium will use the funding to improve the diagnosis of rare diseases. The researchers will work directly with four European reference networks (or ERNs): European networks of care providers set up to share and enhance the knowledge and resources used for treating rare diseases.Patients with a rare disease generally go through a long and arduous process, sometimes lasting ten or fifteen years (also known as the rare disease odyssey), before finding a physician who knows what is wrong with them. Scientific advances can also take a long time, as it is difficult to find sufficient numbers of people with the same rare disease to enable successful research.
No diagnosisCollectively rare diseases are common. While for a given rare disease, the number of people will be extremely low, the very large number of such rare diseases means that collectively, their number in Europe runs into hundreds of thousands. In recent years, it has become clear that the ‘eye’ of a doctor alone often will not suffice to diagnose a rare disease. We need better genetic tests to effectively diagnose rare diseases.
CommitmentThis is where SOLVE-RD, a large-scale research program operating under the European Commission’s Horizon 2020, comes in. The academic partners taking part in SOLVE-RD have designed an infrastructure enabling the coordination and analysis of all data generated across Europe.
Combining the existing exome and genome patient data of all collaborators of SOLVE-RD greatly increases the chances of finding a second or a third patient with the same rare disease. The commitment for sharing data on rare diseases on this scale is unique.
Data as never seen beforeBut SOLVE-RD goes a few steps further by applying the latest available ‘multi-omics’ methods. If the DNA data illuminate a particular disease, researchers turn to other large scale tests that reflect the gene’s function such as RNA, the proteins (proteomics), metabolic products (metabolomics) and epigenomics. Combining these ‘…omics’ techniques provides the extra information that may ensure that a rare disease is diagnosed. The enormous amount of data resulting from this multi-omics approach must be converted into useful, comprehensible information by bioinformatic scientists using smart algorithms.
Virtual networksSOLVE-RD is a unique project, because the research for better diagnostics of rare diseases is directly linked to better care at the European level in 24 Reference Networks (ERNs). These ERNs were set up to improve and harmonize diagnosis and treatment for people suffering from rare diseases. Using shared knowledge and guidelines, a patient in Romania, for example, will receive the same diagnostics and treatment as a patient in Sweden or Spain. The virtual networks collectively pool all existing knowledge and remove unnecessary boundaries.
Diagnostics of the futureSOLVE-RD comprises four ERNs for rare neurological diseases (RND), neuromuscular diseases (EURO-NMD), congenital malformations and intellectual disability (ITHACA) and genetic tumor risk syndromes (GENTURIS). These ERNs are the first to add and share their patient data, thereby taking the lead in improving the diagnosis and treatment of these rare diseases. Other ERNs will join SOLVE-RD later. In this way, SOLVE-RD will have a significant impact on our knowledge and clinical practice when it comes to diagnosing and treating rare diseases in Europe.
The role of Radboud university medical center in SOLVE-RDNicoline Hoogerbrugge (leader of ERN-GENTURIS): “This really empowers patients with hereditary cancer, finding the molecular diagnosis is of great importance for treatment of the patients and prevention of cancer in relatives."
Han Brunner (co-coordinator of SOLVE-RD): "It is a unique emphasis that so many researchers share so much data of so many rare disease patients to boost novel discoveries. Via the involved ERNs we assemble a lot of the rare disease experts from all over Europe."
Alexander Hoischen (workpackage leader SOLVE-RD): "It is exciting to explore the best tests for patients with rare diseases. The human genetic department of the Radboud university center in Nijmegen has always been at the forefront of translating latest genomic tools from research towards diagnostics. With this consortium we can continue to do so with many valued European partners."
Read here an interview that Alexander Hoischen gave to GenomeWeb about SOLVE-RD.
H2020 program: link
- Europa networks: link
- Eurordis: link
Related news items
Evaluation of an AI system for detection of COVID-19 on Chest X-Ray images22 May 2020
In the journal Radiology RIHS researcher Keelin Murphy described how an artificial intelligence system (CAD4COVID-XRay) can identify characteristics of COVID-19 on chest x-rays with performance comparable to six independent radiologists.read more
First clinical trial with genetically modified malaria vaccine completed22 May 2020
In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.read more
New step in the development of a vaccine against malaria22 May 2020
A new vaccine based on rodent malaria parasites achieved a 95% reduction in infection of the liver in humans. An international consortium publishes the results in Science Translational Medicine.read more
Retirement of RIMLS Laboratory Assistant Nelly Mulders-Langen19 May 2020
After more than 45 years, Nelly said goodbye to "her" Radboudumc. We are going to miss her dedication and collegiality, but we wish her al the best for the future in good health.read more